Last reviewed · How we verify

Sonovue and Sonazoid

Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 3 active Small molecule

Sonovue and Sonazoid are ultrasound contrast agents that enhance echocardiographic and ultrasound imaging by producing microbubbles that reflect ultrasound waves.

Sonovue and Sonazoid are ultrasound contrast agents that enhance echocardiographic and ultrasound imaging by producing microbubbles that reflect ultrasound waves. Used for Echocardiographic contrast enhancement for left ventricular opacification, Myocardial perfusion imaging, Cardiac structure and function assessment.

At a glance

Generic nameSonovue and Sonazoid
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Drug classUltrasound contrast agent
ModalitySmall molecule
Therapeutic areaCardiology / Diagnostic Imaging
PhasePhase 3

Mechanism of action

These agents consist of gas-filled microbubbles stabilized by a shell (lipid or protein-based) that circulate through the bloodstream and dramatically increase ultrasound signal reflection, improving visualization of cardiac chambers, myocardial perfusion, and vascular structures. The microbubbles enhance contrast between blood and tissue, enabling better detection of cardiac abnormalities, perfusion defects, and structural lesions during ultrasound imaging.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: